Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Sleep, quality of life, and depression in endometrial cancer survivors with obesity seeking weight loss.

Nock NL, Dimitropoulos A, Zanotti KM, Waggoner S, Nagel C, Golubic M, Michener CM, Kirwan JP, Alberts J.

Support Care Cancer. 2019 Sep 2. doi: 10.1007/s00520-019-05051-1. [Epub ahead of print]

PMID:
31478164
2.

Characterization of Transcriptional Regulatory Networks that Promote and Restrict Identities and Functions of Intestinal Innate Lymphoid Cells.

Pokrovskii M, Hall JA, Ochayon DE, Yi R, Chaimowitz NS, Seelamneni H, Carriero N, Watters A, Waggoner SN, Littman DR, Bonneau R, Miraldi ER.

Immunity. 2019 Jul 16;51(1):185-197.e6. doi: 10.1016/j.immuni.2019.06.001. Epub 2019 Jul 2.

PMID:
31278058
3.

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]

4.

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.

Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, Jackson MW, Xu W, Haider S, DiFeo A, Narla G.

Cancer Res. 2019 Aug 15;79(16):4242-4257. doi: 10.1158/0008-5472.CAN-19-0218. Epub 2019 May 29.

PMID:
31142515
5.

Mutually assured destruction: the cold war between viruses and natural killer cells.

Ali A, Gyurova IE, Waggoner SN.

Curr Opin Virol. 2019 Feb;34:130-139. doi: 10.1016/j.coviro.2019.02.005. Epub 2019 Mar 13. Review.

PMID:
30877885
6.

GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.

Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ.

Gynecol Oncol. 2019 May;153(2):335-342. doi: 10.1016/j.ygyno.2019.02.028. Epub 2019 Feb 28.

7.

Genetic, Inflammatory, and Epithelial Cell Differentiation Factors Control Expression of Human Calpain-14.

Miller DE, Forney C, Rochman M, Cranert S, Habel J, Rymer J, Lynch A, Schroeder C, Lee J, Sauder A, Smith Q, Chawla M, Trimarchi MP, Lu X, Fjellman E, Brusilovsky M, Barski A, Waggoner S, Weirauch MT, Rothenberg ME, Kottyan LC.

G3 (Bethesda). 2019 Mar 7;9(3):729-736. doi: 10.1534/g3.118.200901.

8.

Affinity Maturation Is Impaired by Natural Killer Cell Suppression of Germinal Centers.

Rydyznski CE, Cranert SA, Zhou JQ, Xu H, Kleinstein SH, Singh H, Waggoner SN.

Cell Rep. 2018 Sep 25;24(13):3367-3373.e4. doi: 10.1016/j.celrep.2018.08.075.

9.

Weak vaccinia virus-induced NK cell regulation of CD4 T cells is associated with reduced NK cell differentiation and cytolytic activity.

Hatfield SD, Daniels KA, O'Donnell CL, Waggoner SN, Welsh RM.

Virology. 2018 Jun;519:131-144. doi: 10.1016/j.virol.2018.04.012. Epub 2018 Apr 30.

10.

3T multiparametric MRI-guided high-dose-rate combined intracavitary and interstitial adaptive brachytherapy for the treatment of cervical cancer with a novel split-ring applicator.

Fredman E, Traughber B, Podder T, Colussi V, Zheng Y, Russo S, Herrmann K, Paspulati R, Waggoner S, Zanotti K, Nagel C, Nakayama J, Machtay M, Ellis R.

Brachytherapy. 2018 Mar - Apr;17(2):334-344. doi: 10.1016/j.brachy.2017.09.007. Epub 2017 Oct 31.

PMID:
29097137
11.

Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.

Nagaraj AB, Wang QQ, Joseph P, Zheng C, Chen Y, Kovalenko O, Singh S, Armstrong A, Resnick K, Zanotti K, Waggoner S, Xu R, DiFeo A.

Oncogene. 2018 Jan 18;37(3):403-414. doi: 10.1038/onc.2017.328. Epub 2017 Oct 2.

12.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ.

Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27.

13.

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, Miller DS.

Gynecol Oncol. 2017 Jun;145(3):519-525. doi: 10.1016/j.ygyno.2017.03.017. Epub 2017 Apr 6.

14.

Patient Response to an Integrated Orthotic and Rehabilitation Initiative for Traumatic Injuries: The PRIORITI-MTF Study.

Hsu JR, Owens JG, DeSanto J, Fergason JR, Kuhn KM, Potter BK, Stinner DJ, Sheu RG, Waggoner SL, Wilken JM, Huang Y, Scharfstein DO, MacKenzie EJ; METRC.

J Orthop Trauma. 2017 Apr;31 Suppl 1:S56-S62. doi: 10.1097/BOT.0000000000000795.

PMID:
28323803
15.

Correction: Deletion of Slam locus in mice reveals inhibitory role of SLAM family in NK cell responses regulated by cytokines and LFA-1.

Guo H, Cranert SA, Lu Y, Zhong MC, Zhang S, Chen J, Li R, Mahl SE, Wu N, Davidson D, Waggoner SN, Veillette A.

J Exp Med. 2016 Sep 19;213(10):2227. doi: 10.1084/jem.2016055209072016c. Epub 2016 Sep 12. No abstract available.

16.

Editorial: Natural killer cells "strike" a new cord.

Waggoner SN, Mavilio D.

J Leukoc Biol. 2016 Sep;100(3):449-51. doi: 10.1189/jlb.1CE0416-181RR. No abstract available.

PMID:
27587377
17.

Deletion of Slam locus in mice reveals inhibitory role of SLAM family in NK cell responses regulated by cytokines and LFA-1.

Guo H, Cranert SA, Lu Y, Zhong MC, Zhang S, Chen J, Li R, Mahl SE, Wu N, Davidson D, Waggoner SN, Veillette A.

J Exp Med. 2016 Sep 19;213(10):2187-207. doi: 10.1084/jem.20160552. Epub 2016 Aug 29. Erratum in: J Exp Med. 2016 Sep 19;213(10):2227.

18.

Roles of natural killer cells in antiviral immunity.

Waggoner SN, Reighard SD, Gyurova IE, Cranert SA, Mahl SE, Karmele EP, McNally JP, Moran MT, Brooks TR, Yaqoob F, Rydyznski CE.

Curr Opin Virol. 2016 Feb;16:15-23. doi: 10.1016/j.coviro.2015.10.008. Epub 2015 Nov 16. Review.

19.

Boosting vaccine efficacy the natural (killer) way.

Rydyznski CE, Waggoner SN.

Trends Immunol. 2015 Sep;36(9):536-46. doi: 10.1016/j.it.2015.07.004. Epub 2015 Aug 10. Review.

20.

Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P.

Gynecol Oncol. 2015 Sep;138(3):614-9. doi: 10.1016/j.ygyno.2015.06.038. Epub 2015 Jul 3.

21.

Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.

Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A.

Oncotarget. 2015 Sep 15;6(27):23720-34.

22.

Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer.

Kunos CA, Sherertz TM, Mislmani M, Ellis RJ, Lo SS, Waggoner SE, Zanotti KM, Herrmann K, Debernardo RL.

Front Oncol. 2015 Jun 5;5:126. doi: 10.3389/fonc.2015.00126. eCollection 2015.

23.

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

McMeekin DS, Sill MW, Walker JL, Moore KN, Waggoner SE, Thaker PH, Rizack T, Hoffman JS, Fracasso PM.

Gynecol Oncol. 2015 Jul;138(1):36-40. doi: 10.1016/j.ygyno.2015.04.038. Epub 2015 May 6.

24.

Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells.

Rydyznski C, Daniels KA, Karmele EP, Brooks TR, Mahl SE, Moran MT, Li C, Sutiwisesak R, Welsh RM, Waggoner SN.

Nat Commun. 2015 Feb 27;6:6375. doi: 10.1038/ncomms7375.

25.

Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.

Mahdi H, Elshaikh MA, DeBenardo R, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris RT, Harding J, Moslemi-Kebria M.

Gynecol Oncol. 2015 May;137(2):239-44. doi: 10.1016/j.ygyno.2015.01.544. Epub 2015 Jan 29.

PMID:
25641568
26.

Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.

Mahdi H, Rose PG, Elshaikh MA, Munkarah A, Isrow D, Singh S, Waggoner S, Ali-Fehmi R, Morris RT, Harding J, DeBenardo R.

Gynecol Oncol. 2015 Mar;136(3):529-33. doi: 10.1016/j.ygyno.2014.12.034. Epub 2015 Jan 7.

PMID:
25575483
27.

Hyperthermic Intra-Thoracic Chemotherapy (HITeC) for the management of recurrent ovarian cancer involving the pleural cavity.

Singh S, Armstrong A, Robke J, Waggoner S, Debernardo R.

Gynecol Oncol Case Rep. 2014 May 20;9:24-5. doi: 10.1016/j.gynor.2014.05.001. eCollection 2014 Aug.

28.

NK cells and their ability to modulate T cells during virus infections.

Cook KD, Waggoner SN, Whitmire JK.

Crit Rev Immunol. 2014;34(5):359-88. Review.

29.

TRIM13 is a negative regulator of MDA5-mediated type I interferon production.

Narayan K, Waggoner L, Pham ST, Hendricks GL, Waggoner SN, Conlon J, Wang JP, Fitzgerald KA, Kang J.

J Virol. 2014 Sep;88(18):10748-57. doi: 10.1128/JVI.02593-13. Epub 2014 Jul 9.

30.

Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.

Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.

Invest New Drugs. 2014 Aug;32(4):729-38. doi: 10.1007/s10637-014-0078-5. Epub 2014 Mar 12.

PMID:
24619298
31.

The transcriptional repressor BLIMP1 curbs host defenses by suppressing expression of the chemokine CCL8.

Severa M, Islam SA, Waggoner SN, Jiang Z, Kim ND, Ryan G, Kurt-Jones E, Charo I, Caffrey DR, Boyartchuk VL, Luster AD, Fitzgerald KA.

J Immunol. 2014 Mar 1;192(5):2291-304. doi: 10.4049/jimmunol.1301799. Epub 2014 Jan 29.

32.

Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response.

Cornberg M, Kenney LL, Chen AT, Waggoner SN, Kim SK, Dienes HP, Welsh RM, Selin LK.

Front Immunol. 2013 Dec 20;4:475. doi: 10.3389/fimmu.2013.00475. eCollection 2013.

33.

Self-efficacy, quality of life, and weight loss in overweight/obese endometrial cancer survivors (SUCCEED): a randomized controlled trial.

McCarroll ML, Armbruster S, Frasure HE, Gothard MD, Gil KM, Kavanagh MB, Waggoner S, von Gruenigen VE.

Gynecol Oncol. 2014 Feb;132(2):397-402. doi: 10.1016/j.ygyno.2013.12.023. Epub 2013 Dec 22.

PMID:
24369301
34.

Therapeutic depletion of natural killer cells controls persistent infection.

Waggoner SN, Daniels KA, Welsh RM.

J Virol. 2014 Feb;88(4):1953-60. doi: 10.1128/JVI.03002-13. Epub 2013 Nov 27.

35.

Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, Fusco N, Adams R, Redline R, Faulhaber P, Dowlati A.

Gynecol Oncol. 2013 Jul;130(1):75-80. doi: 10.1016/j.ygyno.2013.04.019. Epub 2013 Apr 18.

36.

Evolving role of 2B4/CD244 in T and NK cell responses during virus infection.

Waggoner SN, Kumar V.

Front Immunol. 2012 Dec 11;3:377. doi: 10.3389/fimmu.2012.00377. eCollection 2012.

37.

Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies.

Kunos CA, Brindle J, Waggoner S, Zanotti K, Resnick K, Fusco N, Adams R, Debernardo R.

Front Oncol. 2012 Dec 5;2:181. doi: 10.3389/fonc.2012.00181. eCollection 2012.

38.

NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections.

Welsh RM, Waggoner SN.

Virology. 2013 Jan 5;435(1):37-45. doi: 10.1016/j.virol.2012.10.005. Review.

39.

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Dec;127(3):506-10. doi: 10.1016/j.ygyno.2012.08.037. Epub 2012 Aug 31.

40.

Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.

von Gruenigen VE, Frasure HE, Smith DA, Fusco NL, Eaton SM, DeBernardo RL, Heugel AM, Waggoner SE.

Anticancer Drugs. 2012 Aug;23(7):724-30. doi: 10.1097/CAD.0b013e32835396d4.

41.

Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial.

von Gruenigen V, Frasure H, Kavanagh MB, Janata J, Waggoner S, Rose P, Lerner E, Courneya KS.

Gynecol Oncol. 2012 Jun;125(3):699-704. doi: 10.1016/j.ygyno.2012.03.042. Epub 2012 Mar 28.

PMID:
22465522
42.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Apr;125(1):54-8. doi: 10.1016/j.ygyno.2011.12.417. Epub 2011 Dec 11.

43.

Natural killer cells act as rheostats modulating antiviral T cells.

Waggoner SN, Cornberg M, Selin LK, Welsh RM.

Nature. 2011 Nov 20;481(7381):394-8. doi: 10.1038/nature10624.

44.

The effect of sleep disturbance on quality of life in women with ovarian cancer.

Sandadi S, Frasure HE, Broderick MJ, Waggoner SE, Miller JA, von Gruenigen VE.

Gynecol Oncol. 2011 Nov;123(2):351-5. doi: 10.1016/j.ygyno.2011.07.028.

PMID:
21855973
45.

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK.

Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12.

46.

Feasibility of a lifestyle intervention for ovarian cancer patients receiving adjuvant chemotherapy.

von Gruenigen VE, Frasure HE, Kavanagh MB, Lerner E, Waggoner SE, Courneya KS.

Gynecol Oncol. 2011 Aug;122(2):328-33. doi: 10.1016/j.ygyno.2011.04.043. Epub 2011 May 19.

PMID:
21600635
47.

A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.

Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS.

Gynecol Oncol. 2011 May 1;121(2):264-8. doi: 10.1016/j.ygyno.2010.12.358. Epub 2011 Feb 1.

48.

Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report.

Starks D, Prinz D, Armstrong A, Means L, Waggoner S, Debernardo R.

Case Rep Obstet Gynecol. 2011;2011:837160. doi: 10.1155/2011/837160. Epub 2011 Sep 8.

49.

Lifestyle challenges in endometrial cancer survivorship.

von Gruenigen VE, Waggoner SE, Frasure HE, Kavanagh MB, Janata JW, Rose PG, Courneya KS, Lerner E.

Obstet Gynecol. 2011 Jan;117(1):93-100. doi: 10.1097/AOG.0b013e31820205b3.

PMID:
21173649
50.

Low-dose-rate brachytherapy for treatment of uterine didelphys malignancy.

Kunos C, Woods C, Colussi VC, Abdul-Karim FW, Waggoner S.

J Clin Oncol. 2011 Feb 10;29(5):e104-6. doi: 10.1200/JCO.2010.31.7545. Epub 2010 Nov 22. No abstract available.

PMID:
21098325

Supplemental Content

Loading ...
Support Center